{
    "clinical_study": {
        "@rank": "105824", 
        "acronym": "IRAB2", 
        "arm_group": [
            {
                "arm_group_label": "MORNING", 
                "arm_group_type": "Active Comparator", 
                "description": "patients continue to take their treatments (RAS blockers and diuretics) on awaking"
            }, 
            {
                "arm_group_label": "EVENING", 
                "arm_group_type": "Experimental", 
                "description": "Patients take their treatments(RAS blockers and diurectics)at bedtime"
            }
        ], 
        "brief_summary": {
            "textblock": "Objective:\n\n      To show that the frequency of aldosterone breakthrough is lower when RAS blockers are given\n      at bedtime compared to on awaking, and to analyze the determinants and consequences of\n      aldosterone breakthrough.\n\n      Duration of the study: Inclusion 2 years, follow-up one year, total 3 years Design:\n      prospective, multicenter, randomized, controlled, open label, two parallel groups.\n\n      Main selection criteria:\n\n      Inclusion criteria\n\n        -  Chronic kidney disease stage 3 to 4,\n\n        -  ACEI (captopril, enalapril, or ramipril), and/or ARB (losartan, valsartan, or\n           irbesartan) on awaking for at least three months,\n\n        -  History of hypertension or proteinuria > 0,5 g/24h or g/g cr\u00e9atininurie. Exclusion\n           criteria\n\n        -  Office blood pressure \u2265 160/100 mmHg,\n\n        -  Anti-aldosterone (spironolactone, eplerenone) or potassium sparing diuretics (modamide,\n           amiloride), or direct renin inhibitor.\n\n      Evaluation criteria:\n\n      Primary: Serum aldosterone levels at one year.\n\n      Secondary:\n\n        -  Serum aldosterone/renin ratio,\n\n        -  24h urine aldosterone,\n\n        -  Significant aldosterone breakthrough defined by a >10% increase of serum aldosterone\n           levels over baseline values,\n\n        -  Aldosterone breakthrough defined by an increase of serum aldosterone levels over\n           baseline values,\n\n        -  HbA1c,\n\n        -  Urinary albumin/creatinine ratio (UACR) on spot morning urine samples,\n\n        -  Systolic home blood pressure (SBP),\n\n        -  Estimated glomerular filtration rate (eGFR) using the MDRD equation."
        }, 
        "brief_title": "RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Rational:\n\n      Serum aldosterone levels may increase despite blockade of the renin angiotensin system (RAS)\n      with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).\n      This aldosterone breakthrough might be associated with bad outcomes: left ventricular\n      hypertrophy, proteinuria and progression of renal failure. Antihypertensive drugs are given\n      either on awaking or at bedtime. RAS is stimulated during nighttime. RAS blockers and\n      diuretics given on awaking may stimulate aldosterone synthesis, and favor aldosterone\n      breakthrough.\n\n      Objective:\n\n      To show that the frequency of aldosterone breakthrough is lower when RAS blockers are given\n      at bedtime compared to on awaking, and to analyze the determinants and consequences of\n      aldosterone breakthrough.\n\n      Duration of the study: Inclusion 2 years, follow-up one year, total 3 years\n\n      Design: prospective, multicenter, randomized, controlled, open label, two parallel groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic kidney disease stage 3 to 4,\n\n          -  ACEI (captopril, enalapril, or ramipril), and/or ARB (losartan, valsartan, or\n             irbesartan) on awaking for at least three months,\n\n          -  History of hypertension or proteinuria > 0,5 g/24h or g/g creatininuria,\n\n          -  Adult with social security insurance,\n\n          -  Informed consent signed.\n\n        Exclusion Criteria:\n\n          -  Office blood pressure \u2265 160/100 mmHg,\n\n          -  Pathology with life expectancy < 1 year,\n\n          -  Anti-aldosterone (spironolactone, eplerenone) or potassium sparing diuretics\n             (modamide, amiloride), or direct renin inhibitor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805362", 
            "org_study_id": "08-API-03"
        }, 
        "intervention": {
            "arm_group_label": [
                "MORNING", 
                "EVENING"
            ], 
            "intervention_name": "Randomization that determine the time of treatment", 
            "intervention_type": "Other", 
            "other_name": "Randomization determine if the treatment will be taken in the morning or in the evening without changing the treatment"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 5, 2013", 
        "location": {
            "contact": {
                "email": "esnault.v@chu-nice.fr", 
                "last_name": "vincent Esnault, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Nice", 
                    "country": "France", 
                    "zip": "06000"
                }, 
                "name": "Department of Nephrology, Nice University Hospital"
            }, 
            "investigator": {
                "last_name": "Vincent Esnault, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "RAS Blockade at Bedtime Versus on Awakening for the Prevention of Aldosterone Breakthrough", 
        "overall_contact": {
            "email": "esnault.v@chu-nice.fr", 
            "last_name": "Vincent ESNAULT, MD"
        }, 
        "overall_contact_backup": {
            "email": "delcont.d@chu-nice.fr", 
            "last_name": "delphine DEL CONT"
        }, 
        "overall_official": {
            "affiliation": "Nice University Hospital", 
            "last_name": "Vincent ESNAULT, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Committee for the Protection of Personnes", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Serum aldosterone levels at one year", 
            "safety_issue": "No", 
            "time_frame": "Level change between baseline and one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805362"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum aldosterone/renin ratio", 
                "safety_issue": "No", 
                "time_frame": "level change between baseline and 12 months"
            }, 
            {
                "description": "Significant aldosterone breakthrough defined by a >10% increase of serum aldosterone levels over baseline values,", 
                "measure": "Significant aldosterone breakthrough  Significant aldosterone breakthrough", 
                "safety_issue": "No", 
                "time_frame": "changes between baseline and one year"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de Nice", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de Nice", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}